3 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 3 Phase 1, 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
Follow Resistant Cancer: new trials by email Literature Review of Resistant Cancer trials Research Report on Resistant Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma Firsekibart + Tislelizumab + Lenvatinib - HCC - Hepatocellular Carcinoma, TP53 Gene Mutation | Not applicable | Not yet recruiting | Tongji Hospital | 25 | 2026-05-01 | 2026-04-17 |
| Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET 18F-FSPG PET/CT in NSCLC, 18F-FSPG PET/CT in HNSCC - Cancer, Diagnosis | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 32 | 2025-02-19 | 2025-04-04 | |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine - Breast Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 42 | 2024-06-27 | 2026-07-28 |
| Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC Lenvatinib Oral Product Plus VIC1911 - Liver Cancer, Hepatocellular Carcinoma | Not applicable | Terminated | RenJi Hospital | 5 | 2023-08-30 | 2026-04-30 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
Recurrence (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Lung Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Acute-Phase Reaction (1) · Bone Neoplasms (1) · Colorectal Neoplasms (1) · Disease (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Neoplasms (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Liver Neoplasms (1)
Neoplasms by Site (6) · Neoplasms (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Disease Attributes (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Breast Diseases (2) · Carcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Liver Diseases (2)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Cell- and Tissue-Based Therapy (1) · Crizotinib (1) · Cyclophosphamide (1) · Doxorubicin (1) · Gemcitabine (1) · Irinotecan (1) · Lomustine (1) · Paclitaxel (1) · Taxes (1) · binimetinib (1) · fludarabine (1) · fludarabine phosphate (1)
UNC Lineberger Comprehensive Cancer Center (2) · Actuate Therapeutics Inc. (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Massachusetts General Hospital (1) · RenJi Hospital (1) · Tongji Hospital (1)
United States (4) · Belgium (1) · Canada (1) · China (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Ashwin Somasundaram, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Yara Abdou, MD (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 35815408, PMID 41981308
P50CA058223 (1)